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Abstract
Many women newly diagnosed with breast cancer and with a
strong family history of breast cancer are referred to a family
cancer service for genetic counselling and for consideration of
genetic testing for germline mutations in cancer predisposition
genes following completion of their cancer treatment. However,
there is growing evidence that mutation status may influence treat-
ment recommendations, and that there may be benefits in having
‘treatment-focused genetic counselling and testing’ available
shortly after cancer diagnosis. This article reviews the literature that
could inform the development of treatment-focused genetic
counselling and testing, including: the rationale for genetic testing
to aid with treatment decisions; the potential benefits of using
mutation or risk status to tailor management; the criteria that may
be used to identify patients most likely to carry germline mutations;
and the evidence regarding women’s decision-making regarding
treatment-focused genetic counselling and testing and the
associated psychological impact.
It is generally recommended that women with breast cancer
and a family history that includes multiple cases of breast
and/or ovarian cancer across several generations should be
referred to a family cancer service for genetic counselling and
consideration of genetic testing for germline mutations in
breast cancer predisposition genes [1,2]. (The majority of
germline mutations will be in the BRCA genes, although a
small proportion of families may also be eligible for TP53
germline mutation screening in relation to Li Fraumeni
Syndrome or PTEN screening if Cowden’s syndrome is
suspected. However, our review will focus on mutation
screening of the BRCA genes due to the rarity of the other
syndromes and the paucity of associated evidence in terms of
the implications for breast cancer management.) Most
women with breast cancer and a relevant family history are
referred following completion of surgery and adjuvant
chemotherapy and/or radiotherapy. The resulting genetic
information may provide the basis for advice regarding their
personal future risk management and for risk clarification for
their unaffected blood relatives [1,2]. Currently, there is
usually little urgency for genetic counselling and testing as
the outcomes have generally not altered or directly influenced
the initial cancer management in an individual patient [3].
However, there is growing evidence that knowledge of BRCA
mutation status or a high likelihood of a hereditary cancer
syndrome may influence specific treatment recommendations
[4-6]. At this time, the major contribution of a confirmed
BRCA mutation status is to the decision between selection of
a breast conserving approach or a therapeutic mastectomy
with or without a contralateral risk-reducing mastectomy. In
the future it may also direct the selection of adjuvant
chemotherapy if agents targeted to BRCA mutation status,
such as the poly (ADP-ribose) polymerase (PARP) inhibitors,
prove effective in clinical trials. Targeted genetic counselling
and testing is now increasingly being offered and used for
surgical management decisions because of the very good
survival from early breast cancer [7] and the technical
advances in genetic testing, which mean genetic test results
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can be available within a few weeks. As the survival from early
breast cancer continues to improve, the importance of
considering the risk of developing a new primary breast cancer
increases and may impact on the surgical management of the
current cancer. Consequently, it seems likely that more women
will be offered genetic counselling and testing for inherited
BRCA mutations shortly after diagnosis and the results used to
determine appropriate cancer therapy [3], primarily as it relates
to the prevention of future cancer risks. Hereafter, genetic
counselling and testing offered shortly after diagnosis while
treatment options are being considered will be referred to as
‘treatment-focused genetic counselling and testing’. Such an
intervention, with all its familial considerations, occurs at a
vulnerable time when the woman is coming to terms with her
diagnosis and making decisions about treatment options.
Linking the results of genetic counselling and testing to
subsequent patient management is likely to impact on
familial cancer services by increasing the number of patients
and their unaffected relatives referred for genetic counselling
and testing and the need for patients to be seen soon after
referral in already under-resourced services. The subsequent
increase in the number of mutation-positive families and the
need to provide additional psychosocial support to these
women and their families will impact even further on services
already struggling under personnel and funding constraints
[8]. For example, in the UK almost 2,200 women under the
age of 40 years (5% of all new female breast cancer cases)
are diagnosed with breast cancer each year [9], and there is
evidence that a significant proportion of these will have a
mutation in either of the BRCA1 or BRCA2 genes. Inclusion
of treatment-focused genetic counselling and testing will
also impact on the current clinical pathways within the
associated breast oncology units. Although the familial
cancer clinic is recognised as part of the multidisciplinary
team, its current role is more consultative in nature and
adoption of treatment-focused genetic counselling and
testing will mean a change to the current management
protocols and established work practices.
This paper highlights the evolving role of treatment-focused
genetic counselling and testing and its application to daily
clinical practice and patient management. There is a growing
need to develop and trial cost-effective clinical pathways for
genetic counselling and testing that are responsive to the
timeframes demanded in acute cancer management. There
will also be a need to address and target resource allocation
to best meet the broader health service needs for individual
patients and their families that will arise as a direct
consequence of referral for genetic counselling to help with
treatment decision-making [8,10]. Clearly, innovative new
service models need to be developed for the delivery of
treatment-focused genetic counselling and testing to patients
in already stretched busy clinics. In particular, the potential
roles of health professionals who are already part of the
patient’s treatment team (including breast surgeons, gynae-
cological oncologists, radiation and medical oncologists) in
the delivery of treatment-focused genetic counselling and
testing require careful consideration.
This paper reviews: the current literature regarding the
potential benefits of using germline BRCA mutation status to
tailor the management of newly diagnosed patients with
breast cancer; the criteria used to identify patients most likely
to carry mutations in the BRCA genes; and the factors that
influence women’s decision-making and attitudes regarding
treatment-focused genetic testing as well as its potential
impact on psychological adjustment and breast surgery
choices. Although the focus of the literature to date has been
on genetic testing for BRCA mutations, it is important to
emphasise that it is not simply genetic testing for BRCA
mutations that is important for directing cancer treatment.
Rather, it is treatment-focused genetic counselling, which
focuses on the potential impact of the personal and family
history of cancer on future cancer risks and may include
genetic testing for mutations in BRCA or other breast cancer
predisposition genes, that provides the hereditary cancer risk
assessment necessary to inform therapeutic choices.
The aim of this paper is to raise awareness of the increasing
role of genetic counselling and testing in the therapeutic
arena and to delineate and highlight the associated research
priorities. The article provides the basis for the formulation of
guidelines as they relate to the use of genetic counselling and
testing to inform treatment in certain newly diagnosed
patients with breast cancer.
Literature search strategy
To provide guidance on the criteria that may be used to select
women for treatment-focused genetic testing, we undertook a
systematic literature search. Studies were included in the
review if they met the following criteria: they assessed
mutation frequency in women with early onset breast cancer
who were unselected for family history; they were published in
a peer-review journal; they were published between January
1997 and October 2008; and they were published in the
English language. Both studies that recruited through
hospitals as well as population-based studies were included.
Studies that included women of all ages (even if they reported
data on young women separately) were excluded. The CD-
ROM databases PubMed (which includes MEDLINE),
PsychInfo, CINAHL, and EMBASE were searched, using the
following key words individually and in combination: ‘breast
cancer’, ‘early onset’, ‘young women’, ‘prevalence’, ‘mutation
frequency’, ‘BRCA1’, ‘BRCA2’. Searches were conducted for
key authors who published in this field. The reference lists
accompanying all publications identified were examined.
Literature research process and results
Articles that met the inclusion criteria were evaluated, and
data from these articles were extracted (BM). The included
articles were checked by a second reviewer to determine if
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they met the inclusion criteria (KT). The literature search
identified 309 references as potentially relevant. After
reviewing these, 22 references were selected for detailed
review (Table 1).
Role of BRCA mutation status in guiding
clinical management of patients newly
diagnosed with breast cancer
Genetic testing and decision-making about breast
cancer surgery
Breast conserving surgery (followed by radiotherapy) is the
treatment of choice for many women diagnosed with an early
breast cancer. Most women with early breast cancer are cured
from their disease [7], and evidence suggests there is no
difference in mortality at 10 years between BRCA mutation
carriers and non-carriers [11]. However, in women who carry a
BRCA mutation, the risk of a recurrence or a new primary in
the ipsilateral breast at 10 years is estimated to be as high as
20% to 50% [12]. The risk at 10 years for a contralateral
second primary cancer is approximately 30% and is modestly
greater for women diagnosed before age 50 years [13,14].
There is good evidence that contralateral risk-reducing
mastectomy decreases the risk of breast cancer by up to 95%
[15-19]. Therefore, as survival from early breast cancer
continues to improve, consideration of the risk of developing a
new primary breast cancer becomes more important if it
impacts on the surgical management of the current cancer.
While the discussion so far has focused on known BRCA
mutation carriers, it is important to emphasise that simply
relying on the presence or absence of a BRCA mutation after
a genetic test is an inadequate assessment of a woman’s
likely future cancer risks. A woman with breast cancer in
whom a BRCA mutation has not been detected with current
techniques may still have a significant risk of developing a
new primary cancer depending on her associated family
history, which, in turn, could still influence her decision
regarding breast conserving surgery. Genetic counselling is
an essential component of the genetic risk assessment in
order to interpret the implications of a genetic test result,
particularly if no mutation can be identified - an ‘uninformative’
result. The clinical implications of an uninformative result
depend on whether or not a woman has a relevant family
history of breast and/or ovarian cancer. Specifically, in a
woman with a strong family history of breast and/or ovarian
cancer, there is no convincing evidence that in the absence
of a detectable mutation there is a substantial reduction in the
chance of ipsilateral and/or contralateral breast cancer. There
is some evidence that the risk of a second primary remains
elevated in BRCA1 and BRCA2 mutation negative families,
especially if the breast cancer was diagnosed early [20].
Thus, women with a relevant family history of breast and/or
ovarian cancer who receive uninformative results may still
reasonably consider risk-reducing surgery on the basis of
their strong family history alone. It is important that the
information is discussed with genetic specialists to ensure
correct interpretation of results, but also that these specialists
understand that absence of a detectable mutation does not
preclude a substantial risk of a further primary.
In other circumstances, specific personal and family features
may mean that an uninformative test may support an assess-
ment that it is less likely there is a hereditary syndrome, thus
reducing estimates of risks for a new ipsilateral or contra-
lateral breast cancer. In this instance, the woman can make
an informed decision and reasonably elect breast conservation.
It is possible that a significant proportion of women found to
have a deleterious mutation would opt for bilateral mastec-
tomy if they had access to this information at diagnosis
[21-25]. If a woman is identified as a BRCA mutation carrier,
the mutation status can be used as a variable in the complex
decision-making process regarding the use of radiotherapy
and the type of surgery. The option of combining definitive
and risk-reducing surgery as a unilateral or bilateral
mastectomy after adjuvant therapy is completed avoids the
need for additional surgery if a woman would have elected
risk-reducing surgery at a later date following delayed genetic
counselling with or without genetic testing [26]. Furthermore,
radiation treatment, which may negatively impact on the
cosmetic outcome of breast reconstructive surgery, may be
able to be avoided.
The discussion so far has focused on the relative roles of
breast conservation versus mastectomy, so it could be argued
that treatment-focused genetic counselling and testing need
not be considered at this vulnerable time if women do not want
to consider a mastectomy. However, we would argue that
although a woman may not want to consider a mastectomy as
her first reaction to a new cancer diagnosis, if she has a
suspicious family history and does not have the opportunity for
a full consultation about the possible associated cancer risks,
she risks not being fully informed about the pros and cons for
all the treatment choices available.
Decision-making about risk-reducing salpingo-
oophorectomy
Women newly diagnosed with breast cancer with a BRCA
mutation may also consider a risk-reducing salpingo-oopho-
rectomy (RRSO) to reduce their significant associated future
ovarian cancer risk [27]. RRSO has been shown to reduce
the risk of ovarian cancer by between 85% [28] and 95%
[29]. It also reduces the risk of subsequent breast cancer by
up to 50% in BRCA1 and BRCA2 mutation carriers [28-31],
with risk reduction being greatest for premenopausal women.
Although the cancer prevention considerations are important,
the main indication for considering such surgery around the
time of cancer diagnosis is because an oophorectomy is also
an effective adjuvant treatment for oestrogen-receptor (ER)
positive premenopausal breast cancer. Furthermore, RRSO
will also permit the use of adjuvant aromatase inhibitors,
Available online http://breast-cancer-research.com/content/10/6/216
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which are superior to tamoxifen but are only effective in
postmenopausal women [32,33]
Potentially increased scope of the future uses of
treatment-focused genetic counselling and testing
There are emerging data that indicate that complete cellular
loss of BRCA1 or BRCA2 function in BRCA-associated
cancers confers increased resistance to agents such as
taxanes [34], and that these tumours are more sensitive to
DNA-damaging agents such as platinum agents [35]. It is
reasonable, therefore, to speculate that the known or likely
BRCA mutation status of a woman could influence systemic
therapy decisions and choice of chemotherapy once we have
more definitive data from randomised trials. Moreover, further
refining of pathological techniques may allow treatment
targeted at aberrant molecular pathways of the tumour, which
may be related to both somatic and germline BRCA
mutations as well as other predictive markers. There is
evidence that BRCA1-associated breast cancers are more
aggressive [36,37], and that adjuvant chemotherapy should
be considered in the majority of mutation positive women,
even those with small, node negative breast cancers.
As well as improvements in the understanding of the relative
efficacies of conventional chemotherapy agents in the
adjuvant treatment of BRCA1 or BRCA2 mutation carriers,
novel agents such as PARP inhibitors have been developed
that exploit the effect of a mutated gene in the associated
cancers. The BRCA1 and BRCA2 genes are important for
DNA double-strand break repair by homologous recombi-
nation. PARP is an enzyme involved in base excision repair, a
key pathway in the repair of DNA single-strand breaks [38].
The inhibition of PARP results in the development of DNA
double-strand breaks that are normally repaired through the
homologous recombination pathway mediated by BRCA1
and BRCA2. The BRCA1 or BRCA2 dysfunction occurring
in cancers arising in BRCA1 or BRCA2 germline mutation
carriers sensitises tumour cells to the inhibition of PARP
enzymatic activity, resulting in chromosomal instability, cell
cycle arrest and apoptosis, as these cells have no functioning
copy of the BRCA genes. The other body cells are relatively
insensitive to the effects of PARP inhibition as these cells still
retain a functioning BRCA1 or BRCA2 gene. Consequently,
the use of PARP inhibitors in BRCA-associated cancer has
the potential for a wide therapeutic index between the effects
of PARP inhibition on tumour and normal body cells [39].
Clinical trials using PARP inhibitors are underway in BRCA-
associated cancers [40]. If successful, and if they progress
into the adjuvant arena, the use of PARP inhibitor agents will
increase the need to ascertain a patient’s BRCA mutation
status around the time of cancer diagnosis. The results of
phase 1 and 2 studies show that PARP inhibitors are very
active agents [41], and it is likely that they will be investigated
in the adjuvant setting for women with early stage breast
cancer within the next few years.
Complexity of decision-making about treatment-
focused genetic counselling and testing
There is a growing awareness of the potential benefits of
understanding a woman’s likely hereditary cancer risk status
for the consideration of simultaneous therapeutic and contra-
lateral risk-reducing mastectomy, better tailoring of con-
ventional adjuvant therapies and the testing of novel agents in
the adjuvant setting. There is a small window of opportunity
to establish the optimal ways in which to offer treatment-
focused genetic counselling and testing and to develop
appropriate associated clinical pathways, in advance of a
more widespread clinical demand.
The development of educational resources that support
women considering genetic counselling and testing to make
informed decisions as well as facilitating discussions
between women and their health professionals is also critical.
These resources will need to provide information for women
to consider the potential advantages and disadvantages of
this process. These include the added stress of undergoing
genetic testing for a hereditary predisposition around the time
of a breast cancer diagnosis; the implications of uninfor-
mative genetic test results; the possibility of delaying surgery
for a short time while waiting for genetic testing results if
there is no planned delay in definitive surgery or radiotherapy
due to neoadjuvant or adjuvant chemotherapy; and the
implications of this information for the wider family.
Raising the issue about the hereditary aspects of breast
cancer at the time of diagnosis involves more than con-
sidering the usual pros and cons of genetic testing and, if a
mutation is found, discussing the role of mastectomy as a
risk-reducing strategy at some time in the future. It adds
another layer of complexity to the decisions around cancer
treatment when providing women with the opportunity to
consider the wider issues that may affect their future survival
and possible disease course rather than using the tumour
staging and characteristics alone. There are a variety of
management options, and this is complex information to
convey at a vulnerable time, so this will require multi-
disciplinary input from breast surgeons, plastic surgeons,
medical and radiation oncologists as well as other health
professionals involved in the care of women with breast
cancer outside traditional genetic counselling services.
Involvement of genetic specialists in the multidisciplinary
team will ensure that these issues are brought up, but also
that patients are not disadvantaged by ill informed application
of these genetic tests. As genetic testing becomes faster and
cheaper, some clinicians might believe that testing results
indicate a clear set of treatment options. It is, however,
essential that the decisions that arise as a result of genetic
testing be considered within the context of the priorities of
treating the current cancer. Integration of a new model of
genetic counselling and testing to help direct therapy may
also challenge assumptions that women who are coping with
a recent diagnosis of breast cancer, and are already making
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multiple decisions about their treatment are not interested in,
or able to cope with, additional information about their
genetic risk.
Targeting of treatment-focused genetic
testing to certain patients with newly
diagnosed breast cancer
The current costs of genetic testing and a climate of cost
constraints mean that treatment-focused genetic testing will
need to be targeted to the women who have a reasonable
chance of being mutation carriers. How to select women
appropriately is problematic. The traditional approach of only
offering genetic testing to women in a potentially high-risk
group based on their family history alone is being challenged
as there is accumulating evidence that many women with
mutations in BRCA1 or BRCA2 genes do not have a classic
family history (Table 1) [42,43]. Other indicators are now also
being considered to provide a basis for the selection for
testing, such as phenotypic pathological characteristics of
the tumour tissue (for example, basal-like phenotype).
Treatment-focused genetic testing will be no different and
case selection should include consideration of the classic
features, including a strong family history of breast and/or
ovarian cancer, younger age at breast cancer diagnosis,
presence of bilateral breast cancer, membership in an ethnic
group with a high incidence of founder mutations (for
example, Ashkenazi Jewish background), in addition to the
tumour tissue characteristics. The evidence available to
support the adoption of such selection criteria are described
briefly below.
Women with a strong family history of breast and/or
ovarian cancer
There is strong evidence that the frequency of mutations in
BRCA1 or BRCA2 genes is increased in women with a
strong family history of breast and/or ovarian cancer involving
multiple generations of affected blood relatives and/or those
with a specific ethnicity or from certain geographical loca-
tions that are associated with known founder mutations. For
example, Malone and colleagues [44] provide a summary of
the literature and report that in women with extensive family
histories, estimates of mutation frequency range from 20% to
50%. There is a consensus that women with strong family
histories of breast and/or ovarian cancer should be offered
genetic counselling and testing for mutations in the two
BRCA genes (for example, National Breast Cancer Centre
[45] and American Society of Clinical Oncology [1,46]).
However, it is also clear that many mutation carriers will be
missed if the presence of a strong family history of breast
cancer and/or ovarian cancer is used as the sole criterion to
offer genetic testing. Table 1 provides a summary of pub-
lished studies on women with early onset breast cancer who
have had genetic testing for BRCA1 and BRCA2 mutations;
it shows that the proportion of women with a BRCA1 or
BRCA2 mutation with no family history of breast/ovarian
cancer ranges from 6% [47] to 78% [48]. The lack of a family
history of breast and/or ovarian cancer can arise because of a
small family size, few female relatives of an age to have
developed cancer, patrilineal inheritance, low cancer
penetrance and non-disclosure of relevant family cancer
diagnoses due to geographic or social distance between
relatives [42,49].
Women with early onset breast cancer
Table 1 also shows that the proportion of women found to
have mutations in BRCA1 or BRCA2 genes varies consi-
derably between studies, ranging from 2.0% to 33.0%. This
variability is likely to be the result of differing populations, age
selection criteria and mutation detection methods utilised.
Studies vary in the extent to which they include women from
ethnic backgrounds characterised by the presence of
founder mutations, which will have specific population
frequencies not applicable to a wider outbred population. The
age selection criteria chosen for different studies also vary
between under 31 to under 55 years. Finally, the diagnostic
sensitivity of the methods used for the detection of BRCA1
and BRCA2 mutations varies [50]. Accordingly, in Table 1
the studies are ranked for sensitivity of the mutation detection
method. Sensitivity estimates are based on published data
only and do not take into account the operator dependence
of these methodologies.
Extracting the data for women aged under 40 years from the
studies in Table 1 gives a BRCA mutation detection rate of
between 4.9% [51] and 23.0% [52]. A prior probability of
mutation detection exceeding 10% [1] is generally considered
sufficiently high to justify genetic testing for BRCA mutations
through many public genetics clinics. It should be noted
though that this threshold is not based on health economic
analyses, and the cut-off to be used will depend on local
availability of resources and ethnic mix.
Women with early onset breast cancer and a family history of
breast/ovarian cancer
Several studies found that women with early onset breast
cancer who have at least one first-degree or one first- and
one second-degree relative with breast or ovarian cancer
have higher mutation frequencies (Table 1) and may be
suitable candidates for treatment-focused genetic testing. For
example, Loman and colleagues [43] found that in women
aged 40 years and under, 39% of women with this degree of
family history carried mutations in BRCA1 or BRCA2. Similarly,
Martinez-Ferrandis and colleagues [53] found that even a
moderate family history was a good predictor of BRCA1 or
BRCA2 mutation status; 15.4% of women with at least one
first-degree relative with breast or ovarian cancer or one case
of male breast cancer were BRCA1 or BRCA2 mutation
carriers. Lalloo and colleagues [47] found an even higher rate
of mutation carriers in women under the age of 31 years with
a first- or second-degree relative with breast and/or ovarian
cancer (44%), compared to those without such a family history.
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Women with early onset bilateral breast cancer
Young women with bilateral breast cancer have a higher
chance of a BRCA mutation than their counterparts with
unilateral disease. For example, Loman and colleagues [43]
found that 33% of women aged 40 and under with bilateral
cancer were BRCA1 or BRCA2 mutation carriers.
Women whose tumours have certain histological characteristics
Tumour pathology is increasingly useful in case selection for
BRCA genetic testing [42]. Specifically, it has been shown
that BRCA1-associated tumours have a distinct immunohisto-
chemical profile associated with the basal-like phenotype [42].
Lakhani and colleagues [54] showed that information on age at
diagnosis, high histological grade and an ER negative receptor
status provides a powerful predictor of BRCA1 mutation status.
Specifically, in women who were aged between 30 and
34 years at diagnosis, the probability of presence of a BRCA1
mutation increased from 5% for women with all histology, to
27% for women with ER negative and grade 3 histology. The
data reported by Lakhani and colleagues suggest that women
aged under 35 years with ER negative breast cancers, regard-
less of grade, have BRCA1 mutation frequencies much greater
than 10%. Similarly, Atchley and colleagues [55] found that 34%
and 8% of women diagnosed with triple negative breast cancer
were BRCA1 and BRCA2 mutation carriers, respectively. How-
ever, the true rate of BRCA1 mutations in ER negative or ‘triple
negative’ (ER, progesterone receptor and HER2 negative)
breast cancer cases is unknown, as there have been no studies
looking at the BRCA1 and BRCA2 mutation prevalence in a
prospectively collected population-based cohort of cases.
Women with early onset breast cancer from populations with
BRCA founder mutations
Specific ethnic factors increase the likelihood of a BRCA1 or
BRCA2 mutation in women with early onset breast cancer.
For example, Abeliovich and colleagues [56] found a fre-
quency of BRCA1 or BRCA2 mutations of 30% in women of
Ashkenazi Jewish background who developed breast cancer
under the age of 40 years. Data from Myriad Genetics clinical
testing service [57] show a BRCA1 or BRCA2 mutation
prevalence of 12% in women of Ashkenazi Jewish ancestry
with breast cancer who are aged less than 50 years and who
have no relevant listed family history. By contrast, the BRCA1
or BRCA2 mutation prevalence in women of Ashkenazi
Jewish ancestry with breast cancer aged 50 and over with no
relevant family history is considerably lower (4%). Founder
mutations have been identified in many populations, including
Swedish, Norwegian, Icelandic, Dutch, Eastern European and
French Canadian to name but a few.
Selective testing of certain subgroups of
women with early breast cancer
In conclusion, these data suggest some specific features that
may guide selection for treatment-focused genetic counsel-
ling and testing, which are summarised in Table 2.
Limited data are currently available on whether to use age 40,
45 or even 50 years as a cut-off to define the group of young
women from each of the four groups described above for an
offer of treatment-focused genetic testing. Hence, a meta-
analysis of existing data and/or more research involving larger
samples will be required to decide on optimal age cut-offs.
Cost considerations are also likely to be a critical factor, and
health economic analyses need to be undertaken to provide a
basis for decisions on which mutation prevalence thresholds
to use for an offer of treatment-focused genetic counselling
and testing consistent with local resources.
Previous attempts at integrating treatment-
focused genetic testing into clinical practice
Several groups have demonstrated that genetic counselling
and testing of newly diagnosed breast cancer patients can be
integrated successfully into clinical practice [12,26,58,59].
Published reports of existing treatment-focused genetic testing
programs used varying criteria for selecting patients for the
offer of such genetic testing. In particular, three used a minimum
of a 10% probability of carrying a BRCA1 or BRCA2 mutation
as assessed by risk assessment models such as BRCAPRO or
that of Myriad Genetics [12,58] or on the basis of data from
published reports [26]. A fourth program utilised a check list
with risk factors thought to be predictive of hereditary breast
cancer, which incorporated both family history of breast and/or
ovarian cancer as well as young age (regardless of family
history) and diagnostic features (bilateral, multifocal and/or multi-
centric breast cancer), again regardless of family history [59].
These programs also differed in terms of which health
professional recommended genetic testing; in one study
women self-referred, typically following a physician recom-
mendation [26]. In other programs, testing was offered by
cancer clinic staff [12,58], or the health professional offering
testing was not specified [59].
The timing of the offer of genetic testing was also variable. In
one program women were offered testing before definitive
surgical treatment, which was defined as either breast
conserving surgery with radiation treatment, or unilateral or
bilateral mastectomy; women who had undergone a lumpec-
tomy but not yet commenced radiation therapy remained
eligible for testing [26]. Similarly, Stolier and colleagues [58]
report that testing results became available either during
systemic therapy, or radiation therapy was delayed until
results were given, while Weitzel and colleagues [12] report
that genetic testing took place either immediately following
biopsy, after breast conserving surgery or during chemo-
therapy. These authors report that definitive surgery was not
delayed to accommodate genetic testing, but that radiation
therapy did not take place where possible until the results
from genetic testing had become available [12,26].
It should be noted that timing of genetic testing before initial
surgery has also been proposed; in particular, Silva [5]
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advocates that genetic counselling and testing be offered
during the window of time when some patients are having
neoadjuvant therapy. Therefore, either neoadjuvant or adju-
vant chemotherapy given prior to radiotherapy can give a
useful window in which to consider treatment-focused
genetic testing before definitive local surgery.
Women’s decision-making about, and the
psychological and behavioural impact of,
treatment-focused genetic testing
Psychological impact of standard genetic testing for
BRCA1 and/or BRCA2 mutations
There is an expanding body of literature about the
psychological impact of genetic testing in affected women at
increased risk for hereditary breast/ovarian cancer who were
offered ‘standard’ genetic testing for BRCA1 and/or BRCA2
mutations, that is, genetic testing offered in the context of
genetic counselling following completion of cancer treatment,
as opposed to treatment-focused genetic counselling and
testing (see Schlich-Bakker and colleagues [60] and Meiser
[61] for reviews). This literature indicates that the impact of
genetic testing is mediated and amplified by women’s former
experience of cancer [61]. Women with a previous diagnosis
of cancer have been found to be significantly more distressed
compared to unaffected women following genetic testing
[62] independently of carrier status [63]. Women for whom
the gap between being diagnosed with cancer and being
genetically tested was less than a year tend to report greater
reductions in well-being compared to those for whom the gap
was longer [64,65]. This may indicate that genetic testing
around the time of diagnosis may place additional
psychological stressors on women or that women feel
frustrated if they realise they might have selected an
alternative therapy had they received genetic counselling
prior to completion of cancer treatment. These results do not
suggest that treatment-focused genetic testing should not
occur, but rather that it should be provided in a supportive
environment that is responsive to these wider issues.
Impact of treatment-focused genetic testing for BRCA1
and/or BRCA2 mutations on surgery decisions
Limited empirical data have been published that describe
women’s decision-making about, and the psychological and
behavioural impact of, treatment-focused genetic testing in
the context of a new diagnosis of breast cancer. In a key US
study, Schwartz and colleagues [21,26,66,67] evaluated the
impact on surgical decision-making in 194 newly diagnosed
breast cancer patients who were offered testing before
definitive surgery. In this study, women with a 10% prior
probability of carrying a BRCA1 or BRCA2 mutation were
offered genetic testing, and test results were made available
within 2 to 3 weeks. Seventy-six percent of the study partici-
pants chose to have BRCA1 and/or BRCA2 testing; the
decision to undergo testing was associated with physician
recommendation and indecision about definitive local treat-
ment [21]. Twenty-one percent of the women who were
tested proceeded with definitive local treatment before
receiving their tests results; delays in the availability of test
results and low levels of anxiety were associated with the
decision to proceed with definitive local treatment [21].
Schwartz and colleagues [21] also found that 48% of women
who were found to carry a BRCA1 or BRCA2 mutation
Available online http://breast-cancer-research.com/content/10/6/216
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Table 2
Features that may guide selection for treatment-focused genetic counselling and testing
Strong family history consistent with Two or more first- or second-degree relatives on one side of the family plus one or more of 
dominantly inherited breast/ovarian cancer the following features on the same side of the familya:
Additional relatives with breast or ovarian cancer
Breast cancer diagnosed before the age of 40 years
Bilateral breast cancer
Breast and ovarian cancer in the same woman
Ashkenazi Jewish ancestry
Breast cancer in a male relative
One or more first- or second-degree relatives with breast cancer at age 45 years or younger 
plus another first- or second-degree relative on the same side of the family with sarcoma 
(bone/soft tissue) at age 45 years or younger
Young age of onsetb especially in combination with: At least one first-degree relative with breast or ovarian cancer; or
Bilateral breast cancer; or
Specific ethnic group with known founder mutations, for example, Ashkenazi Jewish 
ancestry; or
Presence of a triple negative breast tumours (ER, progesterone receptor and HER2 
negative) or their subgroup of basal-cell like tumours
aNational Breast Cancer Centre [96]. bThe age cut-off to be used will depend on local availability of resources and the future cost of mutation detection.
opted for bilateral mastectomy, compared to 4% of women
who declined genetic testing. These findings indicate that
knowledge of a BRCA1 or BRCA2 mutation before definitive
surgery significantly increases the number of women opting
for bilateral mastectomy for both treatment and risk reduction
[26,66,67]. They also suggest that the presentation of the
information about genetic testing by the treating clinician is
an important factor in the final decision to undertake genetic
testing.
Impact of contralateral risk-reducing mastectomy on
psychosocial outcomes
The study by Schwartz and colleagues [26] also found that,
compared with women who chose breast conservation or
unilateral mastectomy, those who chose mastectomy of the
affected breast and contralateral risk-reducing mastectomy of
the unaffected breast did not report diminished quality of life
or decreased distress [67]. These results are consistent with
findings from another study of 435 BRCA1 or BRCA2
carriers that assessed predictors and outcomes of the
decision to undergo contralateral risk-reducing mastectomy
and found no impact on distress outcomes of contralateral
risk-reducing mastectomy [66]. In this latter study the
decision to undergo contralateral risk-reducing mastectomy
(in conjunction with mastectomy of the affected breast)
following treatment-focused genetic testing was associated
with an informative, mutation positive test result, higher
cancer-specific distress at baseline and younger age at
diagnosis [66]. Similarly, in an international cohort of women,
uptake of contralateral mastectomy was found to be asso-
ciated with younger age [68].
In the study by Schwartz and colleagues [26,66] women
opted into the study and received extensive pre- and post-
test genetic counselling; the select nature of the sample and
the unique resources of the study limit the generalisability of
the results to other settings [69]. Although the data reported
by Schwartz and colleagues suggest few adverse psycho-
logical effects of treatment-focused genetic testing, further
controlled studies in a range of different clinical settings are
needed to determine definitively the psychological and
behavioural impact of treatment-focused genetic testing for
BRCA1 and/or BRCA2 mutations.
In another prospective study from The Netherlands, Schlich-
Bakker and colleagues [60,70,71] assessed predictors of the
decision to undergo treatment-focused testing and its
psychological impact in women with breast cancer who were
about to commence adjuvant radiotherapy. The psychological
distress levels of 102 women who met referral criteria for
genetic counselling and testing were compared to those of
182 women who did not meet such criteria. The authors
report that psychological distress levels did not increase after
an active approach for genetic counselling and testing
[60,70]. Of importance in this setting, not having a family
history of breast cancer was found to predict long-term
distress in the combined group of tested and untested
women [60,70]. Of note, of the 102 patients who met referral
criteria, only 57% opted to have genetic testing [71]. Sixty-
four percent of the 102 women were happy with the timing of
genetic testing, while 13% would have preferred an earlier,
and 19% a later, approach [71].
Women’s attitudes and information needs regarding
treatment-focused genetic testing
A small UK study by Arden-Jones and colleagues [72]
explored whether women wanted to be offered information
about genetic testing close to the time of diagnosis. Thirteen
women, who were ascertained through a family cancer
service, were under the age of 40 and were subsequently
identified as BRCA1 or BRCA2 mutation carriers, partici-
pated in focus groups. The majority of women expressed the
view that offering genetic testing around the time of a breast
cancer diagnosis might add too much stress at a time when
women were confronted with multiple demands on their
coping abilities. However, some women supported testing
around the time of breast cancer diagnosis if it could alter
treatment decisions. All agreed that there was no ‘right’ time
for everyone, with women expressing a preference for being
told that the information was available if they wanted it rather
than then being offered the test at the time of their cancer
diagnosis. However, a broad range of views was observed
and indeed some women said they would prefer to be tested
immediately following their breast cancer diagnosis.
Health professionals’ attitudes toward treatment-
focused genetic testing of newly diagnosed women
The study by Arden-Jones and colleagues [72] also found
that health professionals involved in breast cancer care
expressed concerns about informational and emotional
overload caused by offering genetic testing at the time of a
breast cancer diagnosis. Similar views were expressed in a
recent study of 34 Australian cancer genetics practitioners
that was undertaken to identify problematic or ethically
contentious issues in cancer genetics consultations [73]. The
latter study also highlights: the rights of women to be fully
informed when making treatment decisions; the need to
provide emotional support at this vulnerable time; the impor-
tance of including the genetic counsellor in the multi-
disciplinary team and the impact on the delivery of cancer
genetic services with increasing demand for testing [73].
Potential future directions for research on the
psychosocial implications of treatment-focused genetic
testing
This overview of the psychosocial literature shows that
treatment-focused genetic testing for BRCA1 and/or BRCA2
mutations is not associated with adverse psychological and
quality of life outcomes. However, these studies included
almost exclusively women with a family history that indicated
an increased risk for hereditary breast/ovarian cancer, and
very little is known about the psychosocial impact of
Breast Cancer Research    Vol 10 No 6 Meiser et al.
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treatment-focused genetic testing in women without a family
history. This review also shows that very few data are
currently available on: the anticipated implications of genetic
testing for the patient and other family members; patient
preferences in terms of timing of genetic testing information;
mode of delivery of information; and preferred format and
amount of information. Furthermore, no educational interven-
tions have been developed to supplement expert advice and
counselling of women considering treatment-focused
genetic testing.
Given current funding constraints, the potential for routine
testing in the future of newly diagnosed breast cancer
patients also points to a need to develop and evaluate
innovative patient education strategies as time-efficient
means to supplement expert counselling provided by health
professionals. Possible formats of resources include simple
information sheets or more complex communication and
decision aids. Communication aids may be used to facilitate
and structure the discussion between the patient and the
health professional and may also be tailored to the particular
patient and taken home to be shared with other family
members. Decision aids have been shown to improve
understanding of the potential benefits and risks of different
options and to assist patients to consider the personal
importance of these options [74-77].
Conclusion
There is increasing interest in treatment-focused genetic
counselling and testing. This approach is not indicated for
women who would not consider mastectomy or oophorec-
tomy for cancer management because of age considerations
or personal preference as they would have little to gain from
an expedited genetic assessment. Currently, the main utility
of a treatment-focused genetic assessment is to direct
surgical therapy, but if agents targeted to BRCA-associated
tumours move into the adjuvant arena, then the indications for
treatment-focused genetic assessment will increase further.
For those women in whom knowledge of a likely hereditary
cancer syndrome or mutation status might alter their cancer
treatment, we suggest a stepwise approach to their genetic
assessment. Specifically, women who have a strong family
history or develop breast cancer diagnosed at a young age
regardless of family history may benefit from a formal
assessment of the likelihood of a hereditary component to
their breast cancer. If possible, an analysis of a three-
generation pedigree should be undertaken in conjunction
with the woman’s breast cancer pathology. With regard to
women without a relevant family history of breast and/or
ovarian cancer, there will have to be consideration of an age
cut-off for testing depending on local circumstances, local
ethnicities and mutation prevalence as well as financial
considerations, until the cost of genetic testing substantially
reduces. If genetic testing proceeds, it is essential that the
results be interpreted within the context of the specific family
history so that an accurate hereditary risk assessment can be
provided to the patient.
The opportunity currently exists to systematically ascertain
the important clinical and psychosocial implications of
genetic risk determination for hereditary breast cancer in
women newly diagnosed with breast cancer, in advance of
the inevitable widespread clinical implementation of treatment-
focused genetic testing. Ethical practice requires confidence
that information about genetic risk and testing results can be
provided without damaging psychological or behavioural
consequences, and that the genetic information is correctly
interpreted and relayed to the patient by an appropriate
multidisciplinary team. Thus, data on the acceptability of
treatment-focused genetic testing for germline BRCA1 or
BRCA2 mutations and women’s associated information and
communication needs are required urgently.
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